Nanobowl-supported liposomes enhance paclitaxel delivery by improving loading stability and modulating protein corona effect
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Doxil®--the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
2. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption10.1038/s41467-018-05384-1 ↗
3. Porphyrin–phospholipid liposomes permeabilized by near-infrared light10.1038/ncomms4546 ↗
4. Liposomes-enabled cancer chemoimmunotherapy10.1016/j.biomaterials.2024.122801 ↗
5. Advances and Prospects in Integrated Nano-oncology10.26599/NBE.2024.9290060 ↗
6. Innovative Nanomedicine Approaches for Psoriasis: Advancements, Challenges, and Future Directions10.26599/NBE.2025.9290132 ↗
7. Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy10.1016/j.jconrel.2021.12.023 ↗
8. Construction of a liposome dialyzer for the preparation of high-value, small-volume liposome formulations10.1038/nprot.2015.054 ↗
9. Biomimetic proteolipid vesicles for targeting inflamed tissues10.1038/nmat4644 ↗
10. Liposomal paclitaxel formulations10.1016/j.jconrel.2012.09.006 ↗
11. Synthetic vectors for activating the driving axis of ferroptosis10.1038/s41467-024-52312-7 ↗
12. Effects of drug hydrophobicity on liposomal stability10.1111/j.1747-0285.2007.00610.x ↗
13. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs10.1517/17425247.2014.884557 ↗
14. Role of zein incorporation on hydrophobic drug-loading capacity and colloidal stability of phospholipid nanoparticles10.1016/j.colsurfb.2018.07.068 ↗
15. The changing landscape of medicinal chemistry optimization10.1038/s41573-025-01225-1 ↗
16. Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes10.1016/j.ijpharm.2015.02.013 ↗
17. Phospholipid acyl chain length modulation: a strategy to enhance liposomal drug delivery of the hydrophobic bacteriocin Micrococcin P1 to biofilms10.1016/j.ejps.2025.107149 ↗
18. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models10.1038/s41551-019-0385-4 ↗
19. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer
20. Simple weak-acid derivatives of paclitaxel for remote loading into liposomes and improved therapeutic effects10.1039/D0RA03190A ↗
21. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
22. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis10.1073/pnas.2116271119 ↗
23. Interplay of protein corona and immune cells controls blood residency of liposomes10.1038/s41467-019-11642-7 ↗
24. Shrinkage of pegylated and non-pegylated liposomes in serum, Colloids Surf10.1016/j.colsurfb.2013.10.009 ↗
25. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery10.1021/acsami.8b04962 ↗
26. The influence of protein corona on liposomal delivery systems: A comprehensive review10.1016/j.ejps.2025.107166 ↗
27. Nanobowl-Supported Liposomes Improve Drug Loading and Delivery10.1021/acs.nanolett.0c00495 ↗
28. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery10.1038/s41467-024-46331-7 ↗
29. DPH Probe Method for Liposome-Membrane Fluidity Determination10.1007/978-1-0716-2954-3_21 ↗
30. Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity10.1016/j.cell.2020.02.015 ↗
31. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis10.1056/NEJMoa1615887 ↗
32. Microglia mediate forgetting via complement-dependent synaptic elimination10.1126/science.aaz2288 ↗
33. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade10.1038/s43018-022-00444-4 ↗
34. Brain-targeted drug delivery by manipulating protein corona functions10.1038/s41467-019-11593-z ↗
35. Colorimetric determination of phospholipids with ammonium ferrothiocyanate10.1016/0003-2697(80)90269-9 ↗
36. The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency10.1038/s41551-019-0405-4 ↗
37. Atomic Force Microscopic Analysis of the Effect of Lipid Composition on Liposome Membrane Rigidity10.1021/acs.langmuir.6b00741 ↗
38. Measurement of Cell Membrane Fluidity by Laurdan GP: Fluorescence Spectroscopy and Microscopy10.1007/978-1-4939-6634-9_10 ↗
39. Laurdan fluorescence senses mechanical strain in the lipid bilayer membrane10.1016/j.bbrc.2006.06.152 ↗
40. Bending Contributions to Hydration of Phospholipid and Block Copolymer Membranes: Unifying Correlations between Probe Fluorescence and Vesicle Thermoelasticity10.1021/la001678v ↗
41. Visualizing Tension and Growth in Model Membranes Using Optical Dyes10.1016/j.bpj.2018.08.021 ↗
42. Disorder Amidst Membrane Order: Standardizing Laurdan Generalized Polarization and Membrane Fluidity Terms10.1007/s10895-016-1951-8 ↗
43. Comparative Study of Lipid- and Polymer-Supported Membranes Obtained by Vesicle Fusion10.1021/acs.langmuir.2c00266 ↗
44. 9 - MODEL CELL MEMBRANE SURFACES FOR MEASURING RECEPTOR–LIGAND INTERACTIONS
45. Membrane Fusion-Based Drug Delivery Liposomes Transiently Modify the Material Properties of Synthetic and Biological Membranes10.1002/smll.202408039 ↗
46. Lipid domains control myelin basic protein adsorption and membrane interactions between model myelin lipid bilayers
47. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase10.1529/biophysj.104.056788 ↗
48. Nanoparticles Based on Natural Lipids Reveal Extent of Impacts of Designed Physical Characteristics on Biological Functions10.1021/acsnano.3c07461 ↗
49. Separation of liposomes from plasma components using fast protein liquid chromatography10.1006/abio.1999.4049 ↗
50. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors
51. Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions10.1016/j.jconrel.2023.02.022 ↗
52. Reciprocal Interaction with Neutrophils Facilitates Cutaneous Accumulation of Liposomes10.1021/acsnano.4c06638 ↗
53. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD5510.1016/j.jconrel.2019.04.009 ↗
54. Microtubules as a target for anticancer drugs10.1038/nrc1317 ↗
55. Photoswitchable paclitaxel-based microtubule stabilisers allow optical control over the microtubule cytoskeleton10.1038/s41467-020-18389-6 ↗
56. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms10.1038/s41467-022-33037-x ↗